Exendin-4, a long-acting glucagon-like peptide-1 receptor (GLP-1R) agonist, is a potential regulator of feeding behavior through its ability to inhibit gastric emptying, reduce food intake, and induce satiety. GLP-1R activation by exendin-4 induces anorexia; however, the specific populations of neuropeptidergic neurons activated by exendin-4 within the hypothalamus, the central regulator of energy homeostasis, remain unclear. This study determines whether exendin-4 regulates hypothalamic neuropeptide expression and explores the signaling mechanisms involved. The distribution and quantity of exendin-4-induced c-Fos immunoreactivity were evaluated to determine activation of ␣-melanocyte-stimulating hormone/proopiomelanocortin, neuropeptide Y, neurotensin (NT), and ghrelin neurons in hypothalamic nuclei during exendin-4-induced anorexia in mice. Additionally, exendin-4 action on NT and ghrelin transcript regulation was examined in immortalized hypothalamic neurons. With anorexia induced by intracerebroventricular exendin-4, ␣-melanocyte-stimulating hormone/proopiomelanocortin and neuropeptide Y neurons were activated in the arcuate nucleus, with simultaneous activation of NT-expressing neurons in the paraventricular nucleus, and ghrelin-expressing neurons in the arcuate nucleus, paraventricular nucleus, and periventricular hypothalamus, suggesting that neurons in one or more of these areas mediate the anorexic action of exendin-4. In the hypothalamic neuronal cell models, exendin-4 increased cAMP, cAMP response element-binding protein/activating transcription factor-1 and c-Fos activation, and via a protein kinase A-dependent mechanism regulated NT and ghrelin mRNA expression, indicating that these neuropeptides may serve as downstream mediators of exendin-4 action. These findings provide a previously unrecognized link between central GLP-1R activation by exendin-4 and the regulation of hypothalamic NT and ghrelin. Further understanding of this central GLP-1R activation may lead to safe and effective therapeutics for the treatment of metabolic disorders. (Endocrinology 153: 2208 -2222, 2012) T he hypothalamus integrates peripheral and central signals to regulate appetite and energy homeostasis. Recently, glucagon-like peptide-1 (GLP-1) has emerged as a potential negative regulator of feeding behavior (1). The GLP-1 receptor (GLP-1R) is widely expressed in the hypothalamus (2). GLP-1 plays multiple roles in metabolic homeostasis due to its glucoregulatory function and inhibitory action on food and water intake (3, 4). Endogenous GLP-1 has a short plasma half-life because of its rapid degradation by dipeptidyl peptidase-4 (DPP-4);
T he hypothalamus integrates peripheral and central signals to regulate appetite and energy homeostasis. Recently, glucagon-like peptide-1 (GLP-1) has emerged as a potential negative regulator of feeding behavior (1) . The GLP-1 receptor (GLP-1R) is widely expressed in the hypothalamus (2) . GLP-1 plays multiple roles in metabolic homeostasis due to its glucoregulatory function and inhibitory action on food and water intake (3, 4) . Endogenous GLP-1 has a short plasma half-life because of its rapid degradation by dipeptidyl peptidase-4 (DPP-4); therefore, longer-acting GLP-1 analogs, GLP-1R agonists, or DPP-4 inhibitors are under investigation (5) . Exendin-4 is a long-acting GLP-1R agonist peptide that was originally isolated from the salivary gland of the Gila monster, Heloderma suspectum. Currently, exendin-4 and several DPP-4 inhibitors that increase the concentration of intact endogenous GLP-1 by preventing its degradation are used to treat type 2 diabetes. Exendin-4 has been shown to induce weight loss in overweight patients, suggesting that it can regulate food intake and body weight by readily crossing the blood-brain barrier and directly interacting with hypothalamic appetite-regulating centers (6 -8) . However, other clinical trials indicate that DPP-4 inhibitors are weight neutral (9) . These findings suggest that the hypothalamic GLP-1R activation mediated by exendin-4 may differ from that mediated by increased concentrations of intact endogenous GLP-1 achieved through DPP-4 inhibition. That is, although both GLP-1 and exendin-4 act on the hypothalamus to modulate feeding behavior, key differences exist between the anorectic actions of endogenous GLP-1 and exendin-4 (10) . Considering the widespread clinical use of exendin-4, further research is warranted to study the mechanisms underlying the anorectic actions of exendin-4 within the hypothalamus (11) .
The hypothalamus is subdivided into several nuclei consisting of groups of neurons with specific functions. The arcuate nucleus (ARC), paraventricular nucleus (PVN), ventromedial nucleus (VMH), dorsomedial nucleus (DMH), lateral hypothalamus (LH), and periventricular hypothalamic nucleus (PeV) play an important role in the regulation of energy intake and expenditure by integrating central and peripheral orexigenic and anorexigenic signals. It is well established that there are two distinct neuronal populations in the ARC: neuropeptide Y (NPY) and ␣-melanocyte-stimulating hormone (MSH)/ proopiomelanocortin (POMC) neurons. Additionally, anorexigenic neurotensin (NT) is expressed within the ARC (12) (13) (14) , PVN, DMH, and LH (15) , whereas orexigenic ghrelin neurons are present in the ARC, PVN, the internuclear spaces between hypothalamic nuclei, the perifornical region, and the ependymal layer of the third ventricle (12) .
Exendin-4 has been shown to activate neurons in the PVN via GLP-1R-dependent networks (16) . Compelling evidence demonstrates that the GLP-1R located in the PVN, but not in the ARC, reduce food intake (17) , implying that GLP-1R in specific hypothalamic regions have discrete effects on appetite regulation. Furthermore, the finding that GLP-1R expressed on the ARC POMC neurons do not induce anorexia raises the possibility that exendin-4 may activate other, yet to be identified downstream effectors within the hypothalamus to mediate its anorectic effect (17) , such as NT and ghrelin neurons, localized to similar regions as the GLP-1R (18) . Importantly, NT and ghrelin have been shown to play a significant role in feeding and energy homeostasis (1) . Whether exendin-4 exerts its effect directly on NT or ghrelin neurons via GLP-1R activation remains unknown.
The GLP-1R is a G protein-coupled receptor acting through adenylate cyclase, cAMP, and protein kinase A (PKA) activation (19) . Recently, exendin-4 was demonstrated to suppress appetite and reduce body weight by PKA activation in brain stem GLP-1R-expressing neurons (20) . However, in the hypothalamus, the exact neurons activated by exendin-4 to induce anorexia and whether appetite-regulating neuropeptide gene expression is altered within GLP-1R-expressing hypothalamic neurons remain to be determined. We propose that hypothalamic GLP-1R activation by exendin-4 regulates feeding-related neurons and modulates neuropeptide expression via cAMP/PKA activation. Using in vivo and in vitro models, we mapped the hypothalamic neuronal activation by exendin-4, studied the modulation of NT and ghrelin gene expression after exendin-4 treatment, and the signaling mechanisms involved.
Materials and Methods

Animal experiments
Adult C57BL/6 mice were housed individually in plastic rodent cages and maintained on a 12-h light, 12-h dark cycle with ad libitum access to conventional standard rodent chow and water. A 26-gauge stainless steel guide cannula (Plastics One, Roanoke, VA) projecting into the third cerebral ventricle was implanted into each mouse using flat-skull coordinates from bregma (antero-posterior, Ϫ0.825 mm; medio-lateral, 0 mm; dorso-ventral, Ϫ4.8 mm), and correct cannula placement was verified as previously described (21) . Mice were allowed to recover for 7-14 d and were handled daily for at least 1 wk before manipulations. All procedures were carried out in accordance with protocols and guidelines approved by the University of Toronto Animal Care Committee.
Intracerebroventricular (icv) microinjections for feeding study
Exendin-4 was obtained from American Peptide (Sunnyvale, CA). For the animal treatment, exendin-4 was dissolved in 0.9% saline on the day of treatment, and microinjections were administered 1 h before onset of the dark phase. Each mouse received either exendin-4 or 0.9% saline in a total volume of 2 l by slow infusion through a 30-gauge needle. The mice were returned to their home cages with free access to a premeasured amount of chow and water, and the effect of icv exendin-4 on feeding was determined (four mice per treatment group). Changes in food and water intake, and animal weight, were measured at selected time points posttreatment.
Assessment of neuronal activation by c-Fos immunohistochemistry (IHC)
To study the effect of acute stimulation of GLP-1R by exendin-4 on the activation of hypothalamic neuropeptidergic neurons, ad libitum-fed mice (four mice per treatment group) were treated with either icv exendin-4 or 0.9% saline as described above for the feeding study. Two hours after icv injections, mice were anesthetized and perfused transcardially with ice-cold 0.1 M PBS followed by freshly prepared 4% paraformaldehyde solution. The brains were removed immediately, postfixed in 4% paraformaldehyde, cryoprotected in sucrose, snap frozen in an isopentane bath, and stored at Ϫ80 C. Frozen brains were subsequently cut with a cryostat (Leica CM1510S; Leica Microsystems, Heerbrugg, Switzerland) in a rostral to caudal direction in the coronal plane into 20-m sections, and serial sections were stored at Ϫ20 C in cryoprotectant.
The number of c-Fos-, ␣-MSH/POMC-, NPY-, NT-, or ghrelin-immunoreactive neurons in specific hypothalamic regions was quantitatively assessed. The specific primary antibodies and their concentration used for detection of immunoreactivity are as follows: anti-c-Fos (1:25,000; Calbiochem, Mississauga, Ontario, Canada), anti-NT (1:5000; ImmunoStar, Hudson, WI), antighrelin (1:1000; catalog no. H-031-31; rabbit antighrelin antibody to n-octanoyl ghrelin; Phoenix Pharmaceuticals, Burlingame, CA), anti-␣-MSH (1:200; catalog no. H-043-01; Phoenix Pharmaceuticals), and anti-NPY (1:1000; catalog no. H-049-03; Phoenix Pharmaceuticals). For the immunohistological analysis, every other section at 20-m intervals through the hypothalamus was selected throughout the hypothalamic nuclei. The sections were allocated rostral to caudal to visualize the distribution of neuropeptide-or c-Fos-immunoreactive neurons on each hemisphere throughout these nuclei. Evenly spaced sections covering the region Ϫ0.70 to Ϫ1.94 mm from bregma were defined according to the Mouse Brain Atlas of Paxinos and Franklin (22) . The detection of c-Fos, ␣-MSH, NPY, NT, or ghrelin immunoreactivity was performed by conventional avidin-biotin-immunoperoxidase method using diaminobenzidine (DAB) as chromogen (Vectastain ABC Elite kit; Vector Laboratories, Burlington, Canada) (23) . We processed brain sections for IHC staining by tyramide signal amplification method (PerkinElmer, Waltham, MA). IHC for c-Fos was performed with DAB to yield a brown nuclear reaction product, whereas IHC for ␣-MSH/POMC, NPY, NT, and ghrelin was performed using DAB with metal enhancer (cobalt chloride), yielding a more intense blue/black cytoplasmic reaction product (catalog no. D0426; Sigma, St. Louis, MO). Previously dissected brains, stored in 4% paraformaldehyde, from the ghrelin knockout mice (ghrlϪ/Ϫ) (24) and their litter-matched controls were obtained from R. Seeley (University of Cincinnati, Cincinnati, OH). All hypothalamii were snap frozen, sectioned, processed, and imaged according to the protocol outlined above for IHC, with the exception that ghrelin antibody was used at a higher concentration of 1:200, rather than 1:1000.
Immunostained sections were examined under a Zeiss Axioplan 2 microscope outfitted with an AxioCam HRc camera and AXIOVISION 4.2 imaging software (Zeiss, Oberkochen, Germany). For the quantification of cells, every second section throughout the ARC, PVN, DMH, and VMH was taken to visualize the distribution of ␣-MSH/POMC, NPY, NT, or ghrelin neurons throughout these nuclei (total three to four sections per mouse). For each of the ARC, PVN, DMH, and VMH from both sides, an image was captured in a single plane of focus at ϫ40 magnification, and a 0.2-mm 2 box was placed in the center of the selected hypothalamic regions. Cells with brown nuclear staining were considered c-Fos-immunoreactive, whereas cells with dark blue/black cytoplasmic staining were considered ␣-MSH/ POMC-, NPY-, NT-, or ghrelin-positive. The immunoreactive neuronal cells from both hemispheres of four to six sections per each animal were counted in a blind manner, and in each group, the mean value of the cell counts per section of an individual animal was used for statistical analysis. The results were expressed as the ratio of cells coexpressing c-Fos with either ␣-MSH/POMC, NPY, NT, or ghrelin to the total number of respective neuropeptide-immunoreactive cells per 0.2-mm 2 area of the ARC, PVN, DMH, VMH, PeV, or the internuclear regions.
Cell culture and reagents
mHypoA-2/30 and mHypoE-36/1 neurons were grown in DMEM (Sigma, Aspen Forest, Canada), supplemented with 5% fetal bovine serum (HyClone Laboratories, Logan, UT), and 1% penicillin/streptomycin (Life Technologies, Inc., Canada), and maintained at 37 C in an atmosphere of 5% CO 2 (25) . Exendin-4 was obtained from American Peptide. Forskolin was purchased from Sigma-Aldrich (Oakville, Canada). 3-Isobutyl-1-methylxanthine and the PKA inhibitors H-89 and protein kinase inhibitor (PKI) (14-22) amide were obtained from Tocris Bioscience (Ellisville, MO).
One-Step RT-PCR
One-Step RT-PCR was carried out to screen the cells for ghrelin, NT, NPY, POMC, and GLP-1R genes using One-Step RT-PCR kit (QIAGEN, Toronto, Canada). The primer pairs used are as follows: Ghrelin-F, 5Ј-agcatgctctggatggacatg-3Ј and Ghrelin-R, 5Ј-aggcctgtccgtggttacttgt-3Ј; NT-F, 5Ј-ataggaatgaaccttcagctg-3Ј and NT-R, 5Ј-gtaggaggccctcttgagtat-3Ј; NPY-F, 5Ј-taggtaacaagcgaatgggg-3Ј and NPY-R, 5Ј-acatggaagggtcttcaagc-3Ј; POMC-F, 5Ј-atgccgagattctgctacagtcg-3Ј and POMC-R, 5Ј-ttcatctccgttgccaggaaacac-3Ј; and GLP-1R-F, 5Ј-tttgatgactatg cctgctgg-3Ј and GLP-1R-R, 5Ј-agcccatcccactggtgtt-3Ј. Total 200-ng RNA was used for all samples in a total volume of 25 l. The RT protocol used for all genes was 50 C for 30 min, 95 C for 15 min, followed by amplification using 95 C for 15 sec, 60 C for 15 sec, and 72 C for 1 min (40 cycles) and final incubation for 7 min at 72 C. All PCR-amplified products were visualized on 1.2% agarose gel containing ethidium bromide under UV light. The PCR amplicons were verified by purification and sequencing (The Centre for Applied Genomics, Toronto, Canada).
RIA for adenosine 3,5-cAMP
The mHypoA-2/30 and mHypoE-36/1 cells were split into 24-well plates until 80% to 90% confluent. After overnight incubation in serum-free DMEM, cells were washed twice with 1ϫ PBS and pretreated for 5 min with 1 M exendin-9-39 (a GLP-1R antagonist) or vehicle alone before a 10-min treatment with vehicle, forskolin (1 or 10 M), and exendin-4 (10 or 50 nM) and incubated at 37 C. All drugs were diluted in Opti-MEM containing 100 mM 3-isobutyl-1-methylxanthine, a competitive nonselective phosphodiesterase inhibitor that promotes accumulation of intracellular cAMP. Forskolin was used as a positive control. After incubation at 37 C, 1 ml of ice-cold ethanol at Ϫ20 C (final concentration, 77% ethanol) was added to the cells to terminate the reaction. The plates were allowed to sit at Ϫ20 C for 24 h. The cells were then scraped and kept at Ϫ80 C until the amounts of intracellular cAMP were determined in triplicate by using cAMP-RIA kit (Biomedical Technologies, Inc., Stoughton, MA).
Quantitative RT-PCR (qRT-PCR)
Cells were harvested at the indicated time points after treatment with vehicle or exendin-4 (10 nM). Real-time qRT-PCR was performed with 2.0 g of total RNA using SYBR green PCR master mix (Applied Biosystems, Inc., Burlington, Canada) and run on the Applied Biosystems Prism 7000 real-time PCR machine (21) . The sequences of the SYBR primers for the ␥-actin and ghrelin genes are as follows: ␥-actin-SYBR-F, 5Ј-cttccccacgccatcttg-3Ј and ␥-actin-SYBR-R, 5Ј-cccgttcagtcaggatcttcat-3Ј; and ghrelin-SYBR-F, 5Ј-ggaggagctggagatcaggtt-3Ј and ghrelin-SYBR-R, 5Ј-ggcccggccatgctgct-3Ј. Gene-specific TaqMan primers and probe of NT were purchased from Applied Biosystems. Data were represented as threshold cycle (Ct) values, defined as the Ct of PCR at which amplified product was first detected, and analyzed using ABI Prism 7000 SDS software package. Copy number of amplified ghrelin or NT gene was standardized to ␥-actin using the standard curve method. The final fold differences in mRNA expression were relative to the corresponding time-matched control.
SDS-PAGE and Western blot analysis
Protein from 80 -90% confluent mHypoA-2/30 and mHypoE-36/1 cells was prepared as described previously (26) . Protein concentration was determined using the bicinchoninic acid protein assay kit (Thermo Scientific, Rockford, IL). Total protein (20 g) was resolved on SDS-PAGE gels and blotted onto Immun-Blot polyvinyl difluoride membrane (Bio-Rad, Hercules, CA). Phospho-cAMP response element (CRE)-binding protein (CREB) (Ser133, 1:750), c-Fos (1:500), and secondary antibodies were purchased from Cell Signaling Technology (Beverly, MA), and G protein ␤-subunit (1:1000) antibody was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Immunoreactive bands were visualized with horseradish peroxidaselabeled secondary antirabbit IgG at a 1:5000 dilution and enhanced chemiluminescence (ECL Advance kit; GE Healthcare, Princeton, NJ). G protein ␤-subunit was used as a loading control. Phospho-CREB and phospo-activating transcription factor-1 (ATF-1) expressions were normalized to total CREB, and only c-Fos was normalized to G protein ␤-subunit.
Statistical analysis
Data were analyzed using GraphPad Prism software (GraphPad Software, Inc., San Diego, CA). Statistical analysis was performed using one-or two-way ANOVA, and statistical significance was determined by post hoc analysis using Bonferroni test or Student's t test with P Ͻ 0.05.
Results
Effect of icv exendin-4 on food and water intake and animal weight
To test the efficacy of the icv injections, we performed a short-term analysis of exendin-4 effects on food and water intake. We found that icv 100 ng of exendin-4 significantly reduced food in ad libitum-fed wild-type mice, and this effect lasted for at least 24 h (Fig. 1A) . Similarly, water intake was found to be suppressed over a 24-h time period (Fig. 1B) . Furthermore, we found significant weight loss at 24 h in exendin-4-treated mice compared with the saline-treated control mice (Fig. 1C) . The dose of exendin-4 used to induce anorexia was based on a previous report (16) .
Effect of icv exendin-4 on activation of hypothalamic nuclei and neuropeptidergic neurons
As assessed by IHC for c-Fos, a protein encoded by the immediate-early gene c-fos, we noted a distinctive pattern of neuronal activation after the central injection of exendin-4 compared with the saline controls (Fig. 2 , B, C, E, and F). Significant increases in the number of c-Fos-positive neurons were detected in the hypothalamic ARC (increase by 315%), DMH (increase by 214%), PVN (increase by 467%), and PeV (increase by 1927%) but not in LH and VMH (Fig. 2G) . Activation of these hypothalamic regions was expected, because these regions widely express GLP-1R (18). We did not examine the potential activation of other central nervous system areas known to express the GLP-1R, such as certain brain stem nuclei and the central nucleus of the amygdale, because the main aim of this study was to investigate the activation of hypothalamic nuclei involved in feeding regulation.
Our next goal was to determine the neuropeptidergic neurons activated in these regions by performing doublestaining IHC for c-Fos and neuropeptide coexpression (Figs. 3i and 4) . We found that exendin-4 significantly activated ␣-MSH/POMC neurons (by 129%) in the hypothalamic ARC (Fig. 4B ) and also robustly activated NT neurons (by 488%) in the PVN (Fig. 4F) . Both ␣-MSH/ POMC and NT neurons, being anorexigenic, are implicated in the inhibition of appetite. Surprisingly, we found that orexigenic NPY-immunopositive neurons were significantly increased in the ARC (Fig. 4D) , whereas ghrelinimmunoreactive neurons were activated in the ARC, PVN, and PeV of exendin-4-treated mice (Fig. 4H) . We also did not notice any change in the number of neurons expressing only neuropeptide-immunoreactivity in the hypothalamic regions of saline-or exendin-4-treated animals (Fig. 4, A,  C , E, and G). Because there is still some controversy regarding the synthesis of ghrelin in the hypothalamus, we also included a ghrelin knockout mouse control to test our ghrelin antibody. We did not detect staining in the PVN Fig. 3ii and Supplemental Fig. 1 , published on The Endocrine Society's Journals Online web site at http://endo.endojournals.org) or ARC (Supplemental Fig. 1 ) of the ghrelin knockout sections vs. the litter-matched controls. These findings suggest that the induced anorexia may be a function of complex interactions occurring between appetite-regulating anorexigenic and orexigenic neurons in the hypothalamus.
Expression of GLP-1R and appetite-regulating neuropeptides in adult mHypoA-2/30 and embryonic mHypoE-36/1 neurons Based on our in vivo findings that exendin-4 activates NT and ghrelin neurons in the hypothalamus, we investigated direct regulation of hypothalamic NT and ghrelin mRNA expression by exendin-4 using clonal, immortalized hypothalamic cell models. We have previously reported the generation and characterization of embryonic and adult mouse hypothalamic cell lines (21, 25) . Using RT-PCR, we confirmed the presence of GLP-1R mRNA in both adult mHypoA-2/30 and embryonic mHypoE-36/1 neuronal cell models (Fig. 5A) . GLP-1R-positive mouse jejunal tissue served as a positive control. We also analyzed the expression of hypothalamic neuropeptides involved in appetite regulation in these cell lines. Both cell models express ghrelin and NT, and the adult mHypoA- 
-MSH-ir (B), c-Fos-ir and NPY-ir (D), c-Fos-ir and NT-ir (F), or c-Fos-ir and ghrelin-ir (H) indicates that icv exendin-4 activates hypothalamic neuropeptidergic neurons. Note that there was no change in the number of neurons expressing only ␣-MSH-ir (A), NPY-ir (C), NT-ir (E)
, or ghrelin-ir (G) in the hypothalamic regions of saline-or exendin-4-treated animals. Data are represented as mean Ϯ SEM (n ϭ 3-4 mice/group); *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001 vs. saline treatment. Statistical significance was calculated by two-tailed, unpaired t test.
2/30 cells express POMC as well (Fig. 5B) . Currently, there are no hypothalamic cell models reported with a functional endogenous GLP-1R. Therefore, we sought to determine whether the GLP-1R was active in the adult and embryonic neurons by cAMP-RIA after exendin-4 treatment. Forskolin, a known adenylate cyclase activator, was used as a positive control. By cAMP-RIA, we found that exendin-4 increased cAMP levels in mHypoA-2/30 neuronal cell line (Fig. 5C) . Also, in mHypoE-36/1 neuronal cells, exendin-4 significantly increased cAMP content compared with vehicle control (Fig. 5D ). These data indicate that the GLP-1R in these cells are responsive to exendin-4. Further, using exendin-9-39, a GLP-1R antagonist, we studied whether exendin-4 directly activates GLP-1R to stimulate cAMP production (16) . We found that 1 M exendin-9-39 alone did not stimulate cAMP production in both cell models but completely attenuated the stimulatory effect of exendin-4 on cAMP levels, suggesting that exendin-4 stimulates cAMP production via GLP-1R activation in both cell lines (Fig. 5, E and F) .
Activation of CREB/ATF-1 and c-Fos by exendin-4 in the hypothalamic neuronal cells
The key signaling pathway that exendin-4 activates is the cAMP/PKA pathway. We next determined whether this classic GLP-1R signaling pathway is activated by exendin-4 in our hypothalamic adult and embryonic cells. The neuronal cells were treated with 10 nM exendin-4, and activation of CREB/ATF-1 and c-Fos was analyzed over 6 h. By Western blot analysis, we found that exendin-4 significantly induced c-Fos activation in the adult mHypoA-2/30 cell line from 30 min through 4 h after treatment (Fig. 6A) . Further, exendin-4 was found to significantly increase phosphorylation of CREB at Ser133 at 15 and 30 min in the adult neuronal cells, by 53 and 58%, respectively (Fig. 6B) . Similarly, exendin-4 significantly increased phosphorylation of CREB at 5 min in the embryonic cells by 42% (Fig. 6D) . Simultaneously, exendin-4 induced phosphorylation of ATF-1 from 15 to 60 min in the adult neuronal cells with the maximal phosphorylation at 30 min (Fig. 6C) . In the embryonic cells, exendin-4 induced significant increase in ATF-1 phosphorylation at 5 and 30 min (Fig. 6E) .
Activated CREB or ATF-1 bind to a CRE within the promoter region of cAMP/CREB/ATF-1 downstream target genes. This leads to the recruitment of CREB-binding protein (CREB-binding protein/p300), and possibly other nuclear coactivators, to enhance transcription of immediate-early or late-response genes. Thus, phosphorylation of CREB may directly, via CRE, activate c-Fos, which can then heterodimerize with members of the c-Jun, ATF, and JDP families to form the activator protein 1, a transcription factor that in turn regulates target gene expression. Overall, activation of CREB/ATF-1 and c-Fos in our neuronal cells suggests that exendin-4 could potentially regulate downstream target genes that express CRE or activator protein 1 consensus cis-elements in their promoter region.
Regulation of NT and ghrelin mRNA transcript expression by exendin-4
Next, we determined whether exendin-4 regulates mRNA transcript levels of NT and ghrelin. The adult and embryonic hypothalamic neuronal cells were exposed to 10 nM exendin-4 over a 24-h time course. Using real-time qRT-PCR, we found that in the adult mHypoA-2/30 neurons, NT mRNA levels were significantly up-regulated by 52% at 4 h after treatment (Fig. 7A) , whereas in the embryonic mHypoE-36/1 neurons, the effect was more prominent, because the mRNA expression was increased by 64% at 6 h and remained significantly higher by 47% until 24 h (Fig. 7C) . With respect to the ghrelin mRNA expression, we found that exendin-4 caused significant attenuation of mRNA levels by 34% at 1 h after treatment in the adult mHypoA-2/30 cell line (Fig. 7B) . Similarly, exendin-4 suppressed ghrelin mRNA transcript levels by 29% at 4 h after treatment in the embryonic mHypoE-36/1 cell line (Fig. 7D) . However, in the adult mHypoA-2/30 neurons, ghrelin mRNA levels were significantly increased by 78% at the 24-h time point (Fig. 7B) . These results clearly indicate that NT and ghrelin genes are regulated by GLP-1R activation in the hypothalamic neuronal models and complement our findings within the in vivo setting.
Reversal of exendin-4 regulation of NT and ghrelin by PKA inhibitors
We then investigated the involvement of PKA, a cAMPdependent protein kinase, in the regulation of NT and ghrelin mRNA expression by exendin-4. We used pharmacological inhibitors of PKA [H-89 at 5 M and PKI (14) (15) (16) (17) (18) (19) (20) (21) (22) amide at 1 M concentration] to pretreat the adult and embryonic cells for 1 h before exposure to 10 nM exendin-4. PBS and dimethylsulfoxide (DMSO) were used as vehicle controls, because exendin-4 was dissolved in PBS and PKA inhibitors were dissolved in DMSO. Total RNA was isolated at 1, 4, and 24 h after the exendin-4 treatment and analyzed using real-time qRT-PCR. Compared with the vehicle treatments, exendin-4 treatment significantly induced an increase in the NT mRNA levels in mHypoA-2/30 neuronal cells, as well as in mHypoE-36/1 neuronal cells (Fig. 8, A and C) . In contrast, exendin-4 treatment significantly decreased ghrelin mRNA levels in both cell lines (Fig. 8, B and D) .
Further, we found that both PKA inhibitors attenuated the exendin-4-induced increase in NT mRNA expression in both neuronal cells models (Fig. 8, A and C) . On the other hand, PKA inhibition released the attenuation of ghrelin mRNA transcripts caused by exendin-4 (Fig. 8, B and D). We also observed that DMSO appears to basally regulate ghrelin mRNA expression in the mHypoA-2/30 line, because DMSO treatment alone resulted in attenuation of ghrelin mRNA expression compared with PBS treatment (Fig. 8B) . Overall, these results indicate that PKA activation is involved with the regulation of NT and ghrelin mRNA by exendin-4.
Discussion
Exendin-4 has been shown to regulate food intake and energy expenditure via GLP-1R-dependent mechanisms (27) . Using an equivalent central dose, Baggio et al. (27) showed that the anorectic action of central exendin-4 was not simply a nonspecific response, because anorexia was absent in GLP-1R knockout mice, which lack functional GLP-1R. In the present study, using single-label IHC with c-Fos, a marker of neuronal activation, we found that exendin-4, at a dose that induced anorexia, activated hypothalamic ARC, PVN, DMH, and PeV, regions that widely express GLP-1R along with several neuropeptides involved in energy metabolism. Furthermore, using doublelabel IHC, we detected that central exendin-4 significantly activated ␣-MSH/POMC and NPY neurons in the ARC, NT-expressing neurons in the PVN, and ghrelin-expressing neurons in the ARC, PVN, and PeV. Finally, using the adult mHypoA-2/30 and embryonic mHypoE-36/1 hypothalamic neuronal cell models, we found that exendin-4, in a PKA-dependent manner, increased NT mRNA expression while attenuating ghrelin mRNA levels. Overall, our in vivo findings suggest that complex interactions may occur between satiety-and hunger-related neuropeptides in one or more hypothalamic nuclei to mediate the overall anorexic action of exendin-4. Our in vitro findings suggest that regulation of hypothalamic NT and ghrelin may lie downstream of exendin-4 GLP-1R activation. However, the present results must be interpreted with care, because these data may be only applicable to the actions of exendin-4, and not endogenous GLP-1, due to the distinct mechanisms of receptor activation by endogenous GLP-1 and exendin-4 previously described (10, 28, 29) .
A recent finding that GLP-1R activation in the ARC does not induce anorexia via ␣-MSH/POMC or NPY neurons suggests that other mediators, such as anorexigenic NT and orexigenic ghrelin neurons, may be involved. Despite their potential role in the hypothalamic regulation of energy homeostasis (1, 26, 30 -34) , NT and ghrelin have received relatively little attention with respect to appetite regulation. Although it is well established that NT-expressing neurons are expressed in the hypothalamus and exert an anorexigenic action (15, 33) , the existence of central ghrelin-expressing neurons is still controversial, and a general consensus does not exist concerning the source of central ghrelin (35) . Although ghrelin-positive neurons are located within the intact hypothalamus (12, 36 -38) , and display synaptic interactions with POMC, NPY, and other ghrelin-containing neurons (13, 39, 40) , at present, the spectrum of functions and physiological role of ghrelin-expressing neurons in the hypothalamus are yet to be fully elucidated. We found that exendin-4 induced almost a 6-fold increase in NT neuronal activation in the PVN, compared with only less than a 2-fold increase in the ARC. This might explain why the PVN GLP-1R system, but not that of the ARC, is predominant in mediating anorexia, as reported by Sandoval et al. (17) . Although ghrelin neurons are orexigenic, we found that exendin-4 significantly activated these neurons in the ARC, PVN, and PeV. However, whether this neuronal activation translates into stimulation or inhibition is not completely clear. It is possible that the activation of hypothalamic ghrelin neurons may be complementary or compensatory to exert a function other than appetite regulation. Exendin-4 has been shown to induce antiinflammatory action in the peripheral tissues (41) . It also exerts neuroprotective effects on dopaminergic neurons by inhibiting proinflammatory mediators (42) . In this context, because ghrelin is found to exert antiinflammatory and neuroprotective effects (43) , the ghrelin neuronal activation that we observed may be involved in mediating antiinflammatory effects of exendin-4 (41). Interestingly, both orexigenic ghrelin and anorexigenic NT share a common characteristic: to stimulate release of cortocotropinreleasing hormone (an anorexigenic and anxiogenic factor in the PVN) resulting in hypothalamic-pituitary-adrenal (HPA) axis activation and stimulation of glucocorticoid release (44, 45) . Because exendin-4 has been demonstrated to stimulate the HPA axis in rodents and humans (46) , it is important to explore the role of hypothalamic ghrelin and NT in the HPA regulation by GLP-1R agonists. This could elucidate possible reasons for why the GLP-1R knockout mice exhibit paradoxically increased corticosterone responses to stress, even though they appear to have a normal HPA axis (47) . Activation of ARC and PeV neurons (particularly of ghrelin neurons) suggest a possible involvement of ghrelin in glucoregulation and neurogenesis induced by GLP-1R activation (14, 21, 48) .
Given that ARC NPY neurons do not express GLP-1R, the significant activation of these neurons that we observed is quite intriguing. Absence of GLP-1R expression on ARC NPY neurons excludes any direct action of exendin-4, suggesting their indirect activation by other neurons, such as POMC neurons or ␥-aminobutyric acid cells, in the ARC (49) . Because NT was demonstrated to inhibit feeding via NT receptors expressed in the hypothalamic ARC (50), it is possible that the activated PVN NT neurons regulate ARC NPY neurons to ultimately inhibit them. However, whether ARC NPY neurons express NT receptors is not known. Another possibility is that the activated ghrelin-immunopositive neurons in the ARC could influence NPY neurons via synaptic transmission (13) . Given that the ARC GLP-1R system regulates glucose homeostasis (17) , and that ARC NPY neurons are glucose-sensitive neurons directly regulated by exogenous ghrelin (14, 48) , the possible interaction between ARC NPY and ghrelin neurons in exendin-4-mediated glucose regulation needs to be analyzed further.
A striking finding in our study was the absence of c-Fos activation in the VMH, the nucleus involved in the control of satiety (51), and in the LH, the region known to control hunger (52) . However, the lack of c-Fos activation in the hypothalamic VMH was in accordance with very low GLP-1R expression in this region (18) . The lack of c-Fos expression in the LH suggests that the LH is not activated by exendin-4, despite moderate expression of GLP-1R in this region (18) . This result may also indicate that orexigenic melanin-concentrating hormone and orexin neurons in the LH are inhibited by exendin-4. It has been demonstrated that leptin inhibits LH indirectly via the activation of ARC POMC neurons and that when leptin-mediated suppression of LH neurons was reversed via ablation of the ARC, c-Fos expression was increased in LH neurons (53) . This suggests that lack of c-Fos may be due to inhibitory quiescence in the LH neurons via exendin-4-activated ARC POMC neurons.
The intracellular signaling pathways regulating hypothalamic NT and ghrelin gene expression after GLP-1R activation have not been previously established. In pancreatic ␤-cells, GLP-1R activation stimulates adenylate cyclase, thereby increasing cAMP and subsequently activating PKA. Similarly, GLP-1 is shown to activate adenylate cyclase in rodent brain (54) , and in hypothalamic POMC neurons, GLP-1R activation stimulates cAMP/PKA pathway to induce anorectic activity (55) . In the present study, we used hypothalamic adult mHypoA-2/30 and embryonic mHypoE-36/1 neuronal cell models because they are the only hypothalamic cell models that express functional, endogenous GLP-1R, as well as NT and ghrelin. Based on their gene expression profile, we speculate that they originate from the PVN. We found that GLP-1R activation lead to up-regulation of intracellular cAMP in these neuronal cell models (21, 25) and that transcription factors CREB and ATF-1 were activated upon exendin-4 stimulation. Furthermore, activation of c-Fos in the mHypoA-2/30 line suggests that the in vivo activation of c-Fos found in the present study could be mediated through direct activation of GLP-1R-expressing hypothalamic neurons. Further studies are required to determine whether exendin-4 regulates gene expression at the promoter region of these genes.
In summary, our data demonstrate that exendin-4 activates multiple hypothalamic sites where complex interactions may occur between appetite-regulating neuropeptidergic neurons to induce anorexia. The findings from our in vitro model of direct action of exendin-4 on NT and ghrelin gene regulation complement our in vivo findings that NT and ghrelin neurons, in addition to ␣-MSH/ POMC and NPY neurons, can be activated and regulated by central exendin-4. Ultimately, this study provides a previously unrecognized link between exendin-4 action and NT and ghrelin regulation.
